派林生物(000403) - 2021 Q1 - 季度财报

Important Notice The company's Board of Directors, Supervisory Board, and all senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report and assume corresponding legal liabilities, with all directors attending the review meeting - The company's Board of Directors, Supervisory Board, and all senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report and assume corresponding legal liabilities, with all directors attending the review meeting[2] Company Overview The company experienced significant financial growth in Q1 2021, driven by a major asset restructuring that expanded its asset and equity base Key Financial Data and Indicators In Q1 2021, the company achieved strong performance with revenue growing by 35.33% and net profit attributable to shareholders increasing by 125.73%, while total assets and net assets expanded significantly due to major asset restructuring Key Financial Indicators for Q1 2021 | Indicator | Current Period | Prior Year Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Revenue (RMB) | 284,858,855.29 | 210,486,077.76 | 35.33% | | Net Profit Attributable to Shareholders (RMB) | 56,401,730.11 | 24,986,719.12 | 125.73% | | Net Cash Flow from Operating Activities (RMB) | 27,098,832.42 | 47,466,390.75 | -42.91% | | Basic Earnings Per Share (RMB/share) | 0.0891 | 0.0395 | 125.57% | | Total Assets (RMB) | 6,929,174,705.11 | 1,652,617,170.83 (Prior Year-End) | 319.28% | | Net Assets Attributable to Shareholders (RMB) | 5,943,509,367.16 | 965,316,161.64 (Prior Year-End) | 515.71% | - During the reporting period, non-recurring gains and losses totaled 12.24 million RMB, primarily from funds occupation fees collected from non-financial enterprises and government subsidies[4] Shareholder Information As of the end of the reporting period, the company had 14,305 common shareholders, with Hangzhou Zemin Investment Tianhong Investment Partnership (18.37%) and Shenzhen Shipping Health Technology Co., Ltd. (12.50%) as the top two, and two groups of concerted parties identified Top Five Shareholders' Holdings | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Hangzhou Zemin Investment Tianhong Investment Partnership (Limited Partnership) | 18.37% | 134,464,531 | | Shenzhen Shipping Health Technology Co., Ltd. | 12.50% | 91,468,779 | | Harbin Tongzhicheng Technology Development Co., Ltd. | 10.98% | 80,381,128 | | Harbin Lanxiang Biotechnology Consulting Co., Ltd. | 3.13% | 22,916,777 | | Ningbo Guojun Yuanhong Investment Management Co., Ltd. - Ningbo Guojun Yuanfeng Investment Management Partnership (Limited Partnership) | 2.98% | 21,808,400 | - The company's major shareholders include concerted parties: 1. Hangzhou Zemin Investment Tianhong, Zhejiang Private Enterprise United Investment, Hangzhou Zemin Investment Industrial, and Tibet Zheyan; 2. Harbin Tongzhicheng, Harbin Lanxiang, Yang Feng, and Yang Li[7] Significant Matters The company's financial performance and strategic direction were significantly impacted by a major asset restructuring, new strategic partnerships, and the progress of fundraising projects Analysis of Changes in Key Financial Data and Indicators During the reporting period, the company's financial metrics experienced significant fluctuations primarily due to the consolidation of subsidiary Pason, leading to substantial increases in assets, equity, revenue, and a decrease in financial expenses - The significant changes in financial data are primarily due to the completion of a major asset restructuring and the consolidation of subsidiary Pason's financial statements during this period[11][12] Key Balance Sheet Item Changes | Account | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | Change Percentage | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 1,018,181,835.78 | 102,827,084.56 | 890.19% | New funds raised for restructuring project | | Goodwill | 2,714,507,184.61 | 0 | 100% | Arising from consolidation of subsidiary Pason | | Share Capital | 732,010,361.00 | 492,434,666.00 | 48.65% | Issuance of shares for asset acquisition and supporting fundraising | | Capital Reserves | 4,734,919,900.05 | 52,563,580.20 | 8907.99% | Share premium from issuance of shares for asset acquisition and supporting fundraising | Key Income Statement and Cash Flow Statement Item Changes | Account | Current Period (RMB) | Prior Period (RMB) | Change Percentage | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 284,858,855.29 | 210,486,077.76 | 35.33% | Consolidation of subsidiary Pason's revenue | | Research and Development Expenses | 7,168,650.84 | 2,078,572.25 | 244.88% | Increased R&D project investment | | Financial Expenses | -7,207,144.33 | 4,918,633.42 | -246.53% | Deyuan interest income | | Net Cash Flow from Investing Activities | -585,447,611.11 | -6,530,231.51 | -8865.19% | Purchase of wealth management products with idle funds and payment of Deyuan cooperation fees | | Net Cash Flow from Financing Activities | 1,475,136,519.39 | 223,565,170.84 | 559.82% | New funds raised for restructuring project | Progress of Significant Matters During the reporting period, the company completed a major asset acquisition and fundraising, advanced strategic cooperation with Xinjiang Deyuan, signed an agreement with China Cinda, and initiated a company name change - The core event was the completion of a major restructuring involving the issuance of shares and cash payment for asset acquisition, with the target assets transferred on January 21, 2021[13] - The company actively expanded external collaborations, making progress in strategic cooperation with Xinjiang Deyuan and signing a Strategic Cooperation Agreement with China Cinda Asset Management Co., Ltd. Shenzhen Branch[15] Progress of Fundraising Utilization The company successfully raised 1.575 billion RMB net through a non-public offering to support asset acquisition, with 557 million RMB utilized and 1.046 billion RMB remaining, and the plasma station construction project progressing well - The company completed a non-public offering, raising approximately 1.6 billion RMB in total funds, with a net amount of 1.575 billion RMB[17] - As of April 15, 2021, the company had cumulatively utilized 557 million RMB of raised funds, with a remaining balance of 1.046 billion RMB[18] - The raised funds are primarily invested in new and relocated single-plasma collection stations, with projects progressing well and construction fully underway[18] Significant Contracts in Ordinary Operations To expand plasma sources, the company signed a Plasma Supply Cooperation Agreement and a Strategic Cooperation Agreement with Xinjiang Deyuan, aiming to leverage their resources for increased plasma station numbers and mutual benefit - The company signed a Plasma Supply Cooperation Agreement and a Strategic Cooperation Agreement with Xinjiang Deyuan to expand plasma sources and increase plasma stations[20] Wealth Management The company had no entrusted wealth management during the reporting period, but the Board approved using up to 1.48 billion RMB of temporarily idle raised funds for low-risk, short-term principal-protected cash management products - The Board of Directors approved the company's use of up to 1.48 billion RMB of temporarily idle raised funds for cash management, investing in low-risk, short-term principal-protected products[21] Financial Statements This section presents the company's unaudited consolidated and parent company financial statements for Q1 2021, including the balance sheet, income statement, and cash flow statement, reflecting the financial position and operating results post-major asset restructuring Financial Statement Details This section provides the company's unaudited consolidated and parent company financial statements for Q1 2021, including the balance sheet, income statement, and cash flow statement, comprehensively reflecting the company's financial status and operating results after the major asset restructuring Consolidated Balance Sheet As of March 31, 2021, total assets reached 6.93 billion RMB, a 319% increase from the beginning of the year, primarily driven by 2.715 billion RMB in goodwill from consolidation and 1.018 billion RMB in monetary funds from raised capital, while equity attributable to parent company shareholders rose to 5.944 billion RMB, up 516%, mainly due to a significant increase in capital reserves Key Consolidated Balance Sheet Items (March 31, 2021) | Item | Amount (RMB) | Change from Year-Beginning | | :--- | :--- | :--- | | Monetary Funds | 1,018,181,835.78 | +890.19% | | Goodwill | 2,714,507,184.61 | N/A (New) | | Total Assets | 6,929,174,705.11 | +319.28% | | Total Liabilities | 984,227,322.12 | +43.53% | | Capital Reserves | 4,734,919,900.05 | +8907.99% | | Total Equity Attributable to Parent Company Shareholders | 5,943,509,367.16 | +515.71% | Consolidated Income Statement In Q1 2021, the company achieved 285 million RMB in operating revenue, a 35.33% year-on-year increase, with net profit attributable to parent company shareholders significantly growing by 125.73% to 56.40 million RMB, and basic earnings per share reaching 0.0891 RMB, primarily due to expanded consolidation scope post-restructuring Key Consolidated Income Statement Items (Q1 2021) | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 284,858,855.29 | 210,486,077.76 | 35.33% | | Operating Profit | 64,513,519.37 | 35,175,399.00 | 83.40% | | Total Profit | 64,335,574.28 | 31,789,067.97 | 102.38% | | Net Profit Attributable to Parent Company Shareholders | 56,401,730.11 | 24,986,719.12 | 125.73% | | Basic Earnings Per Share | 0.0891 | 0.0395 | 125.57% | Consolidated Cash Flow Statement During the reporting period, net cash flow from operating activities was 27.10 million RMB, a 42.91% decrease year-on-year due to increased plasma collection and purchase payments; net cash outflow from investing activities was 585.45 million RMB, mainly for wealth management and cooperation payments; and net cash inflow from financing activities was 1.475 billion RMB, primarily from raised funds for the restructuring project Consolidated Cash Flow Statement Summary (Q1 2021) | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 27,098,832.42 | 47,466,390.75 | | Net Cash Flow from Investing Activities | -585,447,611.11 | -6,530,231.51 | | Net Cash Flow from Financing Activities | 1,475,136,519.39 | 223,565,170.84 | | Net Increase in Cash and Cash Equivalents | 916,787,740.70 | 264,501,330.08 | Explanation of Financial Statement Adjustments The company adopted new lease accounting standards effective January 1, 2021, choosing not to retrospectively adjust comparable period information but only adjusting retained earnings and related financial statement items at the beginning of the first execution year - The company adopted new lease accounting standards effective January 1, 2021, adjusting relevant financial statement items on the initial adoption date without restating prior comparative data[42] Audit Report The company's first-quarter report for 2021 is unaudited - The company's first-quarter report is unaudited[43]